Artificial Intelligence-based lung quantification platform
Thirona’s state-of-the-art AI platform offers market-unique segmentation and quantification capabilities for a precise and accurate assessment of diseased lung areas from CT scans, including airways, pulmonary vasculature and parenchyma.
LungQ™ platform consists of a comprehensive portfolio of robust measurements, developed based on 20+ years of research and a strong backbone of clinical validation studies. The algorithms are designed to ensure reproducible high-performance outcomes in real-life clinical settings, across a wide range of lung diseases, severities and patient populations, by reliably handling image variability, developed in disease-specific datasets.
LungQ™ Parenchyma suite provides precise quantifications of lung tissue density on a lobar, segmental and subsegmental level, crucial for identifying abnormalities such as emphysema, interstitial changes, pulmonary nodules, and more.
Extended portfolio of measurements, including e.g. lung parenchyma volume, air trapping, lung density, fissure completeness aids in the localized treatment of lung cancer, COPD, ILD, and other lung diseases.
LungQ™ Bronchi suite analyzes bronchial anatomical structures, enabling a deep exploration of bronchial disease.
Quantitative bronchial assessment of mucus impaction, airway thickening and other structural changes can provide critical insights into disease detection and progression over time, in multiple diseases such as chronic bronchitis, cystic fibrosis, asthma, COPD, etc.
LungQ™ Vascular suite uncovers completely novel insights into pulmonary vascular diseases, providing a detailed characterization of the lung vasculature and assessment of chronic perfusion defects, from a non-contrast CT scan.
The vascular analysis enables a non-invasive differentiation between pulmonary hypertension groups and provide previously unknown information on vascular abnormalities in diseases such as COPD and ILD.
Comprehensive lung image analysis
The scalable platform enables us to flexibly combine measurements and tailor the analysis to specific exploratory needs, clinical trial outcomes, population requirements and other factors. Ranging from large multi-site clinical trials to exploratory research, from common to rare lung diseases, LungQ™ guarantees consistently robust and reproducible results.
